Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...

Perseris (risperidone) won approval from the US Food and Drug Administration (FDA), making it the first once-monthly long-acting injectable (LAI) for the illness. It will be particularly ...

Shares in pharmaceuticals group Indivior plunged by a third last week after the drugmaker slashed its profit guidance and revealed it would discontinue sales of Perseris, its schizophrenia drug ...